Contraception
Volume 75, Issue 4 , Pages 245-250 , April 2007

Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research

  • Wesley H. Clark

      Affiliations

    • Gynuity Health Projects, New York, NY 10010, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 448 1230.
    • ,
  • Marji Gold

      Affiliations

    • Department of Family and Social Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USA
    • ,
  • Daniel Grossman

      Affiliations

    • Ibis Reproductive Health, San Francisco, CA 94110, USA
    • ,
  • Beverly Winikoff

      Affiliations

    • Gynuity Health Projects, New York, NY 10010, USA

Received 5 December 2005 ,Revised 31 October 2006 ,Accepted 15 November 2006.

References 

  1. Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect Sex Reprod Health. 2002;34:154–161
  2. Winikoff B. Acceptability of medical abortion in early pregnancy. Fam Plann Perspect 1995:27;142-8, 185
  3. Wiebe ER. Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. Contraception. 1997;55:67–71
  4. Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol. 2000;183(2 Suppl):S44–S53
  5. Gouk EV, Lincoln K, Khair A, Haslock J, Knight J, Cruickshank DJ. Medical termination of pregnancy at 63 to 83 days' gestation. Br J Obstet Gynaecol. 1999;106:535–539
  6. Ashok PW, Flett GM, Templeton A. Termination of pregnancy at 9–13 weeks' amenorrhoea with mifepristone and misoprostol. Lancet. 1998;352:542–543
  7. Ellertson C, Elul B, Ambardekar S, Wood L, Carroll J, Coyaji K. Accuracy of assessment of pregnancy duration by women seeking early abortions. Lancet. 2000;355:877–881
  8. McGalliard C, Gaudoin M. Routine ultrasound for pregnancy termination requests increases women's choice and reduces inappropriate treatments. Br J Obstet Gynaecol. 2004;111:79–82
  9. Savitz DA, Terry JW, Dole N, Thorp JM, Siega-Riz AM, Herring AH. Comparison of pregnancy dating by last menstrual period, ultrasound scanning, and their combination. Am J Obstet Gynecol. 2002;187:1660–1666
  10. Taipale P, Hiilesmaa V. Predicting delivery date by ultrasound and last menstrual period in early gestation. Obstet Gynecol. 2001;97:189–194
  11. Mongelli M, Wilcox M, Gardosi J. Estimating the date of confinement: ultrasonographic biometry versus certain menstrual dates. Am J Obstet Gynecol. 1996;174:278–281
  12. Fielding SL, Schaff EA, Nam NY. Clinicians' perception of sonogram indication for mifepristone abortion up to 63 days. Contraception. 2002;66:27–31
  13. Mol BW, van der Veen F, Bossuyt PM. Symptom-free women at increased risk of ectopic pregnancy: should we screen?. Acta Obstet Gynecol Scand. 2002;81:661–672
  14. Barnhart KT, Simhan H, Kamelle SA. Diagnostic accuracy of ultrasound above and below the beta-hCG discriminatory zone. Obstet Gynecol. 1999;94:583–587
  15. Hajenius PJ, Mol BW, Ankum WM, van der Veen F, Bossuyt PM, Lammes FB. Suspected ectopic pregnancy: expectant management in patients with negative sonographic findings and low serum hCG concentrations. Early Pregnancy. 1995;1:258–262
  16. Dart RG, Mitterando J, Dart LM. Rate of change of serial beta-human chorionic gonadotropin values as a predictor of ectopic pregnancy in patients with indeterminate transvaginal ultrasound findings. Ann Emerg Med. 1999;34:703–710
  17. Ankum WM, Mol BW, Van der Veen F, Bossuyt PM. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril. 1996;65:1093–1099
  18. Grossman D, Ellertson C, Grimes DA, Walker D. Routine follow-up visits after first-trimester induced abortion. Obstet Gynecol. 2004;103:738–745
  19. In:  Sloane P,  Slatt L,  Ebell M,  Jacques L editor. Essentials of family medicine. New York: Lippincott Williams and Watkins; 2002;p. 159
  20. Clark WH, Hassoun D, Gemzell-Danielsson K, Fiala C, Winikoff B. Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France. Eur J Contracept Reprod Health Care. 2005;10:184–191
  21. Henderson J, Hwang A, Harper C, Stewart F. Safety of mifepristone abortions in clinical use. Contraception. 2005;72:175–178
  22. Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003;109:190–195
  23. Schaff EA, Eisinger SH, Franks P, Kim SS. Combined methotrexate and misoprostol for early induced abortion. Arch Fam Med. 1995;4:774–779
  24. Creinin MD. Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. Am J Obstet Gynecol. 1996;174:776–778
  25. van der Lugt B, Drogendijk AC. The disappearance of human chorionic gonadotropin from plasma and urine following induced abortion. Disappearance of HCG after induced abortion. Acta Obstet Gynecol Scand. 1985;64:547–552
  26. Honkanen H, Ranta S, Ylikorkala O, Heikinheimo O. The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy. Hum Reprod. 2002;17:2315–2319
  27. Walker K, Schaff E, Fielding S, Fuller L. Monitoring serum chorionic gonadotropin levels after mifepristone abortion. Contraception. 2001;64:271–273
  28. Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial. JAMA. 1994;272:1190–1195
  29. Ballagh SA, Harris HA, Demasio K. Is curettage needed for uncomplicated incomplete spontaneous abortion?. Am J Obstet Gynecol. 1998;179:1279–1282
  30. Nielsen S, Hahlin M. Expectant management of first-trimester spontaneous abortion. Lancet. 1995;345:84–86
  31. Ankum WM, Van der Veen F. Management of first-trimester spontaneous abortion. Lancet. 1995;345:1179–1180
  32. Cowett AA, Cohen LS, Lichtenberg ES, Stika CS. Ultrasound evaluation of the endometrium after medical termination of pregnancy. Obstet Gynecol. 2004;103:871–875
  33. Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol. 2000;183(2 Suppl):S34–S43

PII: S0010-7824(06)00452-5

doi: 10.1016/j.contraception.2006.11.011

Contraception
Volume 75, Issue 4 , Pages 245-250 , April 2007

Article Tools